Cancer Research · 2022 · 16 citations · 21 references
MedicineCancer BiologyOncologyCarcinogenesisChromatin BiologyMolecular OncologyCancer EpigeneticsChromatinEpigenetic Regulation In CancerHistone ProteinsOncogenic Signaling PathwaysTumor Suppressor GenesEpigenetic DysregulationEpigenetic RegulationHistone H3 Lysine 4 MethylationOncogenic Ras MutationsOncogenic Ras SignalingRas-driven TumorigenesisTumor Promoter MechanismsTumor Suppressor Pathways
Menin is necessary for the formation of the menin/mixed lineage leukemia (MLL) complex and is recruited directly to chromatin. Menin is an important tumor suppressor in several cancer types, including lung cancer. Here, we investigated the role of MLL in menin-regulated lung tumorigenesis. Ablation of MLL suppressed KrasG12D-induced lung tumorigenesis in a genetically engineered mouse model. MLL deficiency decreased histone H3 lysine 4 trimethylation (H3K4me3) and subsequently suppressed expression of the Ras protein-specific guanine nucleotide-releasing factor 1 (Rasgrf1) gene. Rasgrf1 was essential for the GTP-bound active state of Kras and the activation of Kras downstream pathways as well as their cancer-promoting activities. MI-3, a small-molecule inhibitor targeting MLL, specifically inhibited the growth of Kras-mutated lung cancer cells in vitro and in vivo with minimal effect on wild-type Kras lung cancer growth. Together, these results demonstrate a novel tumor promoter function of MLL in mutant Kras-induced lung tumorigenesis and further indicate that specific blockade of the MLL-Rasgrf1 pathway may be a potential therapeutic strategy for the treatment of tumors containing Kras mutations. SIGNIFICANCE: Activation of mutant Kras is dependent on MLL-mediated epigenetic regulation of Rasgrf1, conferring sensitivity to small-molecule inhibition of MLL in Kras-driven lung cancer.
21
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
David A. Barbie, Pablo Tamayo, Jesse S. Boehm et al. · Nature · 2009 · 4.2K citations · Full text
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon, Karen Rex, Anne Y. Saiki et al. · Nature · 2019 · 2.3K citations
Medicine, Oncology, Pharmacology +14
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia
Jolanta Grembecka, Shihan He, Aibin Shi et al. · Nature Chemical Biology · 2012 · 449 citations